JP2012502938A - 癌の治療のためのモノクローナル抗体 - Google Patents

癌の治療のためのモノクローナル抗体 Download PDF

Info

Publication number
JP2012502938A
JP2012502938A JP2011527243A JP2011527243A JP2012502938A JP 2012502938 A JP2012502938 A JP 2012502938A JP 2011527243 A JP2011527243 A JP 2011527243A JP 2011527243 A JP2011527243 A JP 2011527243A JP 2012502938 A JP2012502938 A JP 2012502938A
Authority
JP
Japan
Prior art keywords
dsm
antibody
cancer
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011527243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502938A5 (cg-RX-API-DMAC10.html
Inventor
ウグル サヒン，
エズレム テューレヒ，
ミヒャエル コスロフスキー，
リタ ミットナハト−クラウス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg-Universität Mainz
Original Assignee
Johannes Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg-Universität Mainz filed Critical Johannes Gutenberg-Universität Mainz
Publication of JP2012502938A publication Critical patent/JP2012502938A/ja
Publication of JP2012502938A5 publication Critical patent/JP2012502938A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011527243A 2008-09-16 2009-09-16 癌の治療のためのモノクローナル抗体 Pending JP2012502938A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277.9 2008-09-16
US61/097,453 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
PCT/EP2009/006704 WO2010031551A2 (en) 2008-09-16 2009-09-16 Monoclonal antibodies for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2012502938A true JP2012502938A (ja) 2012-02-02
JP2012502938A5 JP2012502938A5 (cg-RX-API-DMAC10.html) 2012-10-25

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527243A Pending JP2012502938A (ja) 2008-09-16 2009-09-16 癌の治療のためのモノクローナル抗体

Country Status (27)

Country Link
US (1) US8946388B2 (cg-RX-API-DMAC10.html)
EP (3) EP2166021A1 (cg-RX-API-DMAC10.html)
JP (1) JP2012502938A (cg-RX-API-DMAC10.html)
KR (1) KR101818741B1 (cg-RX-API-DMAC10.html)
CN (3) CN105753988A (cg-RX-API-DMAC10.html)
AU (1) AU2009294896B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0918178B8 (cg-RX-API-DMAC10.html)
CA (1) CA2732594C (cg-RX-API-DMAC10.html)
CY (1) CY1119956T1 (cg-RX-API-DMAC10.html)
DK (1) DK2342234T3 (cg-RX-API-DMAC10.html)
ES (1) ES2659718T3 (cg-RX-API-DMAC10.html)
HK (1) HK1253579A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20180262T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036477T2 (cg-RX-API-DMAC10.html)
IL (2) IL211010A (cg-RX-API-DMAC10.html)
LT (1) LT2342234T (cg-RX-API-DMAC10.html)
MX (2) MX357010B (cg-RX-API-DMAC10.html)
NO (1) NO2342234T3 (cg-RX-API-DMAC10.html)
NZ (2) NZ596490A (cg-RX-API-DMAC10.html)
PL (1) PL2342234T3 (cg-RX-API-DMAC10.html)
PT (1) PT2342234T (cg-RX-API-DMAC10.html)
RS (1) RS56937B1 (cg-RX-API-DMAC10.html)
SI (1) SI2342234T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201800079T1 (cg-RX-API-DMAC10.html)
TR (1) TR201802090T4 (cg-RX-API-DMAC10.html)
WO (1) WO2010031551A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201100835B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522329A (ja) * 2010-03-23 2013-06-13 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのモノクローナル抗体

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP5940093B2 (ja) * 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
US20170073415A1 (en) * 2014-05-12 2017-03-16 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
ES2820768T3 (es) * 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
KR20180027568A (ko) * 2015-07-14 2018-03-14 메디뮨 엘엘씨 암을 치료하기 위한 조성물 및 방법
AU2016315889A1 (en) * 2015-09-04 2018-03-22 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
MX2018006333A (es) * 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
JP2020513819A (ja) * 2017-03-15 2020-05-21 スージョウ ギャラクシー バイオファーマ カンパニー リミテッド Ｃｔｌａ４抗体、医薬組成物およびその使用
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5389675B2 (ja) * 2007-03-14 2014-01-15 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのモノクローナル抗体

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) * 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
CN100379882C (zh) 2003-01-17 2008-04-09 香港中文大学 作为妊娠相关病症的诊断标志物的循环mRNA
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
MX2011008430A (es) * 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5389675B2 (ja) * 2007-03-14 2014-01-15 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのモノクローナル抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014009597; Ｃａｎｃｅｒ　Ｒｅｓ．，Ｖｏｌ．６７，Ｎｏ．１９（２００７）ｐ．９５２８-９５３４ *
JPN6014009599; Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ，Ｖｏｌ．１２２（Ｍａｙ　２００８）ｐ．２０３８-２０４３ *
JPN6014009601; ＤＲ．　ＲＡＩＮＥＲ　ＷＥＳＳＥＬ，"Ｎｅｕｅ，　ｈｏｃｈ　ｔｕｍｏｒｓｐｅｚｉｆｉｓｃｈｅ　Ａｎｔｉｋｏｒｐｅｒ　ｕｎｄ　ｉｈｒｅ　Ｔａｒｇｅｔｓ"［Ｏｎｌｉｎｅ］　Ｎｏｖｅｍｂｅｒ　２００７，ｐ． *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522329A (ja) * 2010-03-23 2013-06-13 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのモノクローナル抗体

Also Published As

Publication number Publication date
PL2342234T3 (pl) 2018-07-31
WO2010031551A2 (en) 2010-03-25
HK1253579A1 (en) 2019-06-21
US20110223182A1 (en) 2011-09-15
US8946388B2 (en) 2015-02-03
AU2009294896A1 (en) 2010-03-25
DK2342234T3 (en) 2018-02-26
EP2342234B1 (en) 2017-11-15
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
ES2659718T3 (es) 2018-03-19
CA2732594A1 (en) 2010-03-25
NO2342234T3 (cg-RX-API-DMAC10.html) 2018-04-14
CN102164963A (zh) 2011-08-24
CY1119956T1 (el) 2018-12-12
NZ596490A (en) 2013-05-31
ZA201100835B (en) 2014-04-30
WO2010031551A3 (en) 2010-09-16
EP2166021A1 (en) 2010-03-24
HUE036477T2 (hu) 2018-07-30
CN105753988A (zh) 2016-07-13
BRPI0918178B8 (pt) 2021-05-25
CN104628858A (zh) 2015-05-20
SI2342234T1 (en) 2018-04-30
BRPI0918178A2 (pt) 2015-12-01
BRPI0918178B1 (pt) 2021-04-06
KR101818741B1 (ko) 2018-01-15
EP3312198A1 (en) 2018-04-25
NZ591004A (en) 2012-03-30
LT2342234T (lt) 2018-03-12
IL242204A0 (en) 2015-11-30
PT2342234T (pt) 2018-02-21
RS56937B1 (sr) 2018-05-31
CN104628858B (zh) 2018-11-16
HRP20180262T1 (hr) 2018-03-23
IL242204B (en) 2020-09-30
EP2342234A2 (en) 2011-07-13
KR20110055699A (ko) 2011-05-25
TR201802090T4 (tr) 2018-03-21
MX2011002856A (es) 2011-06-28
BRPI0918178A8 (pt) 2020-05-19
SMT201800079T1 (it) 2018-03-08
IL211010A (en) 2015-11-30
CN102164963B (zh) 2015-07-29
IL211010A0 (en) 2011-04-28
MX357010B (es) 2018-06-22

Similar Documents

Publication Publication Date Title
US8946388B2 (en) Monoclonal antibodies for treatment of cancer
JP5843822B2 (ja) 癌の治療のためのモノクローナル抗体
US10596256B2 (en) Monoclonal anti-GT 468 antibodies for treatment of cancer
AU2015205868B2 (en) Monoclonal antibodies for treatment of cancer
HK40000187A (en) Monoclonal antibodies for treatment of cancer
HK1157362B (en) Monoclonal anti-gt468 antibodies for treatment of cancer
HK1157362A (en) Monoclonal anti-gt468 antibodies for treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141021